Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Pancreatic Neoplasms 1Pain 1Neurofibrosarcoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 12Temozolomide 11Radiotherapy 8Radiation 5Surgical Procedures, Operative 3Biopsy 3trametinib 2dabrafenib 2Spinal Puncture 2Radiotherapy, Intensity-Modulated 2Genetic Therapy 2Craniotomy 2Bevacizumab 2vorasidenib 1vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tocilizumab 1ribociclib 1pembrolizumab 1atezolizumab 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Standard of Care 1Restraint, Physical 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × AZD 6244 × 90 days × Clear all
NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
217 enrolled
CNS

Astrocytoma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡